GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (STU:MEB) » Definitions » Total Receivables

Medincell (STU:MEB) Total Receivables : €2.17 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Medincell Total Receivables?

Medincell's Total Receivables for the quarter that ended in Sep. 2023 was €2.17 Mil.


Medincell Total Receivables Historical Data

The historical data trend for Medincell's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Total Receivables Chart

Medincell Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Receivables
Get a 7-Day Free Trial 0.41 0.67 0.92 0.82 2.11

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.82 1.18 2.11 2.17

Medincell Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Medincell Total Receivables Related Terms

Thank you for viewing the detailed overview of Medincell's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Medincell (STU:MEB) Business Description

Traded in Other Exchanges
Address
3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (STU:MEB) Headlines

No Headlines